JPH0335287B2 - - Google Patents

Info

Publication number
JPH0335287B2
JPH0335287B2 JP55129125A JP12912580A JPH0335287B2 JP H0335287 B2 JPH0335287 B2 JP H0335287B2 JP 55129125 A JP55129125 A JP 55129125A JP 12912580 A JP12912580 A JP 12912580A JP H0335287 B2 JPH0335287 B2 JP H0335287B2
Authority
JP
Japan
Prior art keywords
coq
mixture
composition
fluidized bed
oleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP55129125A
Other languages
Japanese (ja)
Other versions
JPS5754116A (en
Inventor
Teruyoshi Nasu
Takayuki Oowaki
Sumio Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Priority to JP12912580A priority Critical patent/JPS5754116A/en
Publication of JPS5754116A publication Critical patent/JPS5754116A/en
Publication of JPH0335287B2 publication Critical patent/JPH0335287B2/ja
Granted legal-status Critical Current

Links

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は分散のよいCoQ10含有組成物に関す
る。CoQ10は冠抹能の改善に有効な医薬品として
近年、臨床上広く利用されるに至つているもので
ある。この物質は48−52℃の融点を有する常温で
固体状の脂溶性物質であり、生体においては主と
してリンパ管から吸収されるものであることが知
られている。 しかしながら、この物質は水に対する分散性が
悪く、また吸収量も僅かなものであり、製剤技術
上解決すべき多数の問題を抱えている。 本発明者はCoQ10の分散性、吸収性の改良のた
めに種々の検討を行つて来た。まず、本発明者の
一人は、特願昭54−110365に示すごとく、CoQ10
をその1部と乳化剤0.05部以上を含有する組成物
であつて、噴霧乾燥法により製造した組成物とす
ることにより、良好に分散化するものとすること
に成功した。 他方、CoQ10の吸収においては、CoQ10の分散
性が重要な要素であり、しかも組成中にゴマ油も
しくはオレイン酸および親水性天然高分子が配合
された噴霧乾燥された場合には、著しく吸収がよ
くなることも知つた。 かかる知見にもとづき、本発明者はCoQ10とオ
レイン酸との混合物をさらに分散性のよいものと
することを課題にして検討を行い、その結果、噴
霧乾燥法に代えて流動層造粒法によつて製造した
場合に分散性が向上することを知り、本発明を完
成した。 すなわち、本発明の要旨はCoQ10とオレイン酸
との混合物に親水性天然高分子またはセルローズ
誘導体が配合される固形組成物を流動層造粒法に
よつて製造することによつて分散のよいCoQ10
有組成物を得ることである。 本発明における親水性天然高分子とは動物また
は植物基源の高分子であるが、親水性があるため
に、分子全体としては分散化力があるものであつ
て、アラビヤゴム、トラガカント、ミルクカゼイ
ン、卵アルブミン、ゼラチンである。 また本発明におけるセルローズ誘導体とはメチ
ルセルローズ、ヒドロキシプロピルメチルセルロ
ーズ、ヒドロキシプロピルエチルセルローズ、カ
ルボキシメチルセルローズナトリウムであつて、
やはり分散化力を有するものである。 これらの親水性天然高分子またはセルローズ誘
導体の量はCoQ10とオレイン酸との混合物を分散
化し、その分散が流動層造粒を終るまでの間安定
である量であればよく、最低必要量はCoQ10とオ
レイン酸との混合物の1重量部に対して0.1重量
部である。 本発明者の一人は先にCoQ10の吸収のためには
脂肪もしくは脂肪分解物がCoQ10に共存すること
が好ましいことを知つた。後に脂肪としてゴマ油
が、また脂肪分解物としてオレイン酸が良いこと
を知つた。かかる観点から、本発明においては、
CoQ10とオレイン酸との混合物の場合が含まれ
る。すなわち、当該構成は吸収促進を目的とする
ものであるが、CoQ10単独の場合と同様に本発明
の課題である分散化向上の処理を受けるべき対象
でもあるから本発明に含まれる。 また、オレイン酸の量はCoQ101重量部に対し
て5重量部以下である。これ以上では分散化剤が
いたずらに増大するのみであり、好ましくない。 また本発明の組成物には、増量剤としてデキス
トリン、コーンスターチ、乳糖、結晶セルロー
ズ、マンニトールを配合することは自由であり、
増量剤の種類並びに配合量については特に制限は
ない。要するに実施する流動層造粒の条件および
本発明の組成物中におけるCoQ10の希望含有量に
応じて適宜に選択すればよい。 本発明において実施する流動層造粒は常法によ
つて行えばよく、方法および条件には特別の制限
はないが、例えば流動層をつくる乾燥空気の入口
温度を70−80℃に設定する。また流動層造粒を行
うための装置としては例えばWSG15(グラツト
社)、FL10(フロイント社)を使用することがで
きる。 次に流動層造粒法によつて得られる本発明組成
物の各粒子は見掛け上は球形の粒状体であるが、
電子顕微鏡による観察によれば数ミクロン程度の
小片が多数個集合した塊状を呈しており、同一組
成について転動造粒法あるいは押出造粒法によつ
て製造したものとは明らかに識別することができ
る。各粒子の粒径は20−200ミクロン程度である
が、これは使用した増量剤の種類および配合量並
びに流動層造粒の条件によつて異なつたものとな
る。また本発明の組成物の見掛比重は0.2〜0.8程
度である。 本発明の組成物は散剤としてそのまま投与して
もよいが、さらに適当な賦形剤を加えて投与をい
つそう容易ならしめる剤型とすることができる。
すなわち、結合剤を加えて細粒剤、顆粒剤とする
こと、さらに圧縮して錠剤とすること、あるいは
細粒剤もしくは顆粒剤カプセルに充填してカプセ
ル剤とすることができる。 次に本発明の組成物がCoQ10の良好な分散をも
たらす効果のあることを以下の効果例によつて明
らかにする。 効果例 試 料 (1) 試料組成 CoQ10 5部 オレイン酸 5部 カゼイン 10部 デキストリン 5部 コーンスターチ 60部 乳 糖 15部 計 100部 (2) 調 製 流動層造粒品 分散化剤をあらかじめ少量の水に分散し、
これにCoQ10とオレイン酸を加え乳化分散液
とした。この分散液を、結晶セルローズ、コ
ーンスターチ、乳糖、デキストリン等の混合
物を流動させた流動層中に噴霧(入口温度80
℃)して各組成の流動層造粒品とした。 押出造粒品 分散化剤をあらかじめ少量の水に分散し、
これにCoQ10とオレイン酸を加え、乳化分散
液とした。この分散液を、結晶セルローズ、
コーンスターチ、乳糖、デキストリン等の混
合物に加えて練合し、20メツシユのスクリー
ンを通して造粒し、50℃で3時間乾燥して各
組成の押出造粒品とした。なおGの組成の押
出造粒品は調製不可能であつた。 分散度測定法 各試料の分散性は、次の方法によつて求め
た。試料100mgを精製水100mlに加え、沈降法用
測定シリンダーに入れ、25℃暗所に24時間静置
後、シリンダー下部の所定位置(下より8cm)
からサンプリングする。このサンプリング液を
エタノールで希釈し、275nmの吸光度を測定
し、サンプリング液1ml中に存在するユビデカ
レノンの重量(Umg)を求める。分散度(%)
は次式により導出する。 分散度(%)=U×100 なお、分散性は分散度50%以下においては明
瞭に沈降分離が見られるので、分散度が50%以
上となる試料については分散性良好とみなす。 実験結果 (1)に示す組成による流動層造粒品および押し
出し造粒品の分散度を表1に示す
The present invention relates to a well-dispersed CoQ 10- containing composition. CoQ 10 has recently come to be widely used clinically as a drug effective for improving coronary peripheral function. This substance is a fat-soluble substance that is solid at room temperature and has a melting point of 48-52°C, and is known to be absorbed mainly through lymph vessels in living bodies. However, this substance has poor dispersibility in water and only a small amount of absorption, and has many problems that need to be solved in terms of formulation technology. The present inventor has conducted various studies to improve the dispersibility and absorbability of CoQ 10 . First, one of the inventors of the present invention proposed CoQ 10 as shown in Japanese Patent Application No. 54-110365.
By using a composition containing 1 part of the above and 0.05 part or more of an emulsifier and produced by a spray drying method, we succeeded in achieving good dispersion. On the other hand, the dispersibility of CoQ 10 is an important factor in the absorption of CoQ 10 , and when it is spray-dried with sesame oil or oleic acid and hydrophilic natural polymers in its composition, absorption is significantly reduced. I also knew it would get better. Based on this knowledge, the present inventors investigated how to make the mixture of CoQ 10 and oleic acid even more dispersible, and as a result, they decided to use the fluidized bed granulation method instead of the spray drying method. The present invention was completed based on the knowledge that the dispersibility was improved when the product was produced in a similar manner. That is, the gist of the present invention is to produce well-dispersed CoQ by producing a solid composition in which a hydrophilic natural polymer or a cellulose derivative is blended with a mixture of CoQ 10 and oleic acid by a fluidized bed granulation method. 10- containing composition. The hydrophilic natural polymer in the present invention is a polymer of animal or plant origin, and due to its hydrophilicity, the molecule as a whole has a dispersing power, such as gum arabic, tragacanth, milk casein, etc. egg albumin and gelatin. Furthermore, the cellulose derivatives in the present invention include methylcellulose, hydroxypropylmethylcellulose, hydroxypropylethylcellulose, sodium carboxymethylcellulose,
After all, it has the power of decentralization. The amount of these hydrophilic natural polymers or cellulose derivatives may be such that the mixture of CoQ 10 and oleic acid is dispersed and the dispersion remains stable until the end of fluidized bed granulation, and the minimum required amount is The amount is 0.1 part by weight per part by weight of the mixture of CoQ 10 and oleic acid. One of the inventors of the present invention previously found that for the absorption of CoQ 10 , it is preferable for fat or lipolysis products to coexist with CoQ 10 . Later, I learned that sesame oil is a good fat and oleic acid is a good fat decomposition product. From this point of view, in the present invention,
This includes the case of a mixture of CoQ 10 and oleic acid. That is, although the purpose of this composition is to promote absorption, it is included in the present invention because it is also subject to treatment for improving dispersion, which is the subject of the present invention, as in the case of CoQ 10 alone. Further, the amount of oleic acid is 5 parts by weight or less per 1 part by weight of CoQ 10 . If the amount is more than this, the amount of dispersing agent will increase unnecessarily, which is not preferable. Furthermore, the composition of the present invention may optionally contain dextrin, cornstarch, lactose, crystalline cellulose, and mannitol as fillers.
There are no particular restrictions on the type and amount of the filler. In short, it may be appropriately selected depending on the conditions of the fluidized bed granulation to be carried out and the desired content of CoQ 10 in the composition of the present invention. The fluidized bed granulation carried out in the present invention may be carried out by a conventional method, and there are no particular restrictions on the method and conditions, but for example, the inlet temperature of the dry air used to form the fluidized bed is set at 70-80°C. Further, as an apparatus for performing fluidized bed granulation, for example, WSG15 (Glatz) and FL10 (Freund) can be used. Next, each particle of the composition of the present invention obtained by the fluidized bed granulation method appears to be a spherical granule, but
According to observation using an electron microscope, it appears to be in the form of a large number of small pieces of several microns, and it is clearly distinguishable from those produced by rolling granulation or extrusion granulation with the same composition. can. The particle size of each particle is approximately 20-200 microns, but this varies depending on the type and amount of filler used and the conditions of fluidized bed granulation. Further, the apparent specific gravity of the composition of the present invention is about 0.2 to 0.8. The composition of the present invention may be administered as a powder as is, but suitable excipients may be added to form a dosage form that facilitates administration.
That is, it can be made into fine granules or granules by adding a binder, it can be further compressed into tablets, or it can be filled into fine granules or granule capsules to make capsules. Next, it will be clarified by the following effect examples that the composition of the present invention has the effect of providing good dispersion of CoQ 10 . Example of effect Sample (1) Sample composition CoQ 10 5 parts Oleic acid 5 parts Casein 10 parts Dextrin 5 parts Cornstarch 60 parts Lactose 15 parts Total 100 parts (2) Prepared fluidized bed granulated product Add a small amount of dispersing agent in advance dispersed in water,
CoQ 10 and oleic acid were added to this to form an emulsified dispersion. This dispersion was sprayed into a fluidized bed containing a mixture of crystalline cellulose, cornstarch, lactose, dextrin, etc. (inlet temperature 80°C).
°C) to obtain fluidized bed granulated products of each composition. Extrusion granulation product Dispersing agent is dispersed in a small amount of water in advance,
CoQ 10 and oleic acid were added to this to form an emulsified dispersion. This dispersion is mixed into crystalline cellulose,
The mixture was added to a mixture of cornstarch, lactose, dextrin, etc., kneaded, passed through a 20-mesh screen, and granulated, and dried at 50°C for 3 hours to obtain extrusion granules of each composition. It should be noted that it was impossible to prepare an extrusion granulated product having the composition of G. Dispersity Measurement Method The dispersibility of each sample was determined by the following method. Add 100 mg of the sample to 100 ml of purified water, put it in a sedimentation measurement cylinder, let it stand in a dark place at 25°C for 24 hours, and then place it at the specified position at the bottom of the cylinder (8 cm from the bottom).
Sample from. This sampling solution is diluted with ethanol, and the absorbance at 275 nm is measured to determine the weight (Umg) of ubidecarenone present in 1 ml of the sampling solution. Dispersity (%)
is derived from the following equation. Dispersity (%) = U x 100 Since sedimentation separation is clearly seen when the dispersibility is 50% or less, samples with a dispersity of 50% or more are considered to have good dispersibility. Experimental Results Table 1 shows the degree of dispersion of fluidized bed granules and extrusion granules with the compositions shown in (1).

【表】 以上の実験結果より、CoQ10とオレイン酸との
混合物に親水性天然高分子またはセルローズ誘導
体が配合される固形組成物であつて、流動層造粒
法によつて製造されるものが、良好な分散性を与
えることが判明する。 以下、実施例により本発明をより詳細に説明す
る。 実施例 1 アラビヤゴム200gを水2に加えて分散し、
70℃に加温してCoQ10400gを加え、混合して乳
化分散液とした。乳糖2Kg、コーンスターチ2
Kg、結晶セルローズ3.4Kgの混合物を流動させた
流動層(乾燥空気の入口温度80℃)中に前記乳化
分散液を噴霧した。全液量を噴霧後さらに10分間
流動乾燥した。得られたCoQ10含有組成物は7.5
Kgであつた。 この粉粒体100mgを4号カプセルに充填し、1
カプセル当りCoQ105mgを含有するカプセル剤を
製造した。 実施例 2 ヒドロキシプロピルセルローズ30g、乳糖70g
に水400mlを加えて分散し、70℃に加温して、
CoQ10100gおよび水600mlを加え混合し、乳化分
散液とした。結晶セルローズ400g、コーンスタ
ーチ200g、乳糖200gの混合物を流動させた流動
層(乾燥空気の入口温度70℃)中に前記乳化分散
液を噴霧した。全液量を噴霧後さらに10分間流動
させ乾燥した。得られたCoQ10含有組成物950g
に少量のステアリン酸マグネシウムを加え、直径
6mmで重量100mgの錠剤に製造した。 実施例 3 ヒドロキシプロピルセルローズ40g、シヨ糖エ
ステル1gに水500mlを加えて分散し、70℃に加
温して、CoQ10100gを加え混合し、乳化分散液
とした。乳糖1000g、マンニツト859gの混合物
を流動させた流動層(乾燥空気の入口温度70℃)
中に前記乳化分散液を噴霧した。全液量を噴霧後
さらに5分間流動させ乾燥した。得られたCoQ10
含有組成物は1965gであつた。この粉粒体を32メ
ツシユの篩を通し、細粒剤を製造した。
[Table] From the above experimental results, a solid composition in which a hydrophilic natural polymer or a cellulose derivative is blended with a mixture of CoQ 10 and oleic acid, which is produced by the fluidized bed granulation method, is confirmed. , is found to give good dispersibility. Hereinafter, the present invention will be explained in more detail with reference to Examples. Example 1 200g of gum arabic was added to 2 parts of water and dispersed,
The mixture was heated to 70° C., 400 g of CoQ 10 was added, and mixed to obtain an emulsified dispersion. 2 kg of lactose, 2 kg of cornstarch
The emulsified dispersion was sprayed into a fluidized bed (dry air inlet temperature: 80° C.) in which a mixture of 3.4 kg of crystalline cellulose and 3.4 kg of crystalline cellulose was fluidized. After spraying the entire liquid amount, fluidized drying was further performed for 10 minutes. The resulting CoQ 10 -containing composition is 7.5
It was Kg. Fill 100 mg of this powder into a No. 4 capsule, and
Capsules were prepared containing 10 5 mg of CoQ per capsule. Example 2 Hydroxypropyl cellulose 30g, lactose 70g
Add 400ml of water to disperse, heat to 70℃,
100 g of CoQ 10 and 600 ml of water were added and mixed to form an emulsified dispersion. The emulsified dispersion was sprayed into a fluidized bed containing a mixture of 400 g of crystalline cellulose, 200 g of corn starch, and 200 g of lactose (dry air inlet temperature: 70° C.). After the entire liquid was sprayed, it was allowed to flow for an additional 10 minutes and dried. 950 g of the resulting CoQ 10 -containing composition
A small amount of magnesium stearate was added to the solution to form tablets with a diameter of 6 mm and a weight of 100 mg. Example 3 40 g of hydroxypropyl cellulose and 1 g of sucrose ester were dispersed in 500 ml of water, heated to 70° C., and 100 g of CoQ 10 was added and mixed to obtain an emulsified dispersion. Fluidized bed containing a mixture of 1000 g of lactose and 859 g of mannitrate (dry air inlet temperature 70°C)
The emulsified dispersion was sprayed into the container. After the entire liquid was sprayed, it was allowed to flow for an additional 5 minutes and dried. Obtained CoQ 10
The composition contained was 1965g. This powder was passed through a 32-mesh sieve to produce fine granules.

Claims (1)

【特許請求の範囲】 1 CoQ10とオレイン酸の混合物に、親水性天然
高分子またはセルローズ誘導体を含有する固形組
成物であつて、流動層造粒法によつて製造される
ことを特徴とするCoQ10含有組成物。 2 CoQ10とオレイン酸との混合物1重量部に親
水性天然高分子またはセルローズ誘導体の0.1重
量部以上を含有する特許請求の範囲第1項記載の
CoQ10含有組成物。 3 混合物がCoQ101重量部とオレイン酸5重量
部以下との混合物である特許請求の範囲第1項お
よび第2項記載のCoQ10含有組成物。
[Claims] 1. A solid composition containing a hydrophilic natural polymer or a cellulose derivative in a mixture of CoQ 10 and oleic acid, characterized in that it is produced by a fluidized bed granulation method. CoQ 10 -containing composition. 2. The method according to claim 1, wherein 1 part by weight of the mixture of CoQ 10 and oleic acid contains 0.1 part by weight or more of a hydrophilic natural polymer or a cellulose derivative.
CoQ 10 -containing composition. 3. The CoQ 10- containing composition according to claims 1 and 2, wherein the mixture is a mixture of 1 part by weight of CoQ 10 and 5 parts by weight or less of oleic acid.
JP12912580A 1980-09-19 1980-09-19 Coenzyme q10-containing composition of high dispersibility Granted JPS5754116A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP12912580A JPS5754116A (en) 1980-09-19 1980-09-19 Coenzyme q10-containing composition of high dispersibility

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP12912580A JPS5754116A (en) 1980-09-19 1980-09-19 Coenzyme q10-containing composition of high dispersibility

Publications (2)

Publication Number Publication Date
JPS5754116A JPS5754116A (en) 1982-03-31
JPH0335287B2 true JPH0335287B2 (en) 1991-05-27

Family

ID=15001697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP12912580A Granted JPS5754116A (en) 1980-09-19 1980-09-19 Coenzyme q10-containing composition of high dispersibility

Country Status (1)

Country Link
JP (1) JPS5754116A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009001787A1 (en) * 2007-06-22 2008-12-31 Kaneka Corporation Composition containing coenzyme q10

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52136912A (en) * 1976-05-06 1977-11-16 Eisai Co Ltd Solia agent
JPS5492616A (en) * 1977-12-28 1979-07-23 Ota Pharma Ubidecalenone soft capsule preparation
JPS54160713A (en) * 1978-06-05 1979-12-19 Kali Chemie Pharma Gmbh Medical preparation with improved absorbability and production

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52136912A (en) * 1976-05-06 1977-11-16 Eisai Co Ltd Solia agent
JPS5492616A (en) * 1977-12-28 1979-07-23 Ota Pharma Ubidecalenone soft capsule preparation
JPS54160713A (en) * 1978-06-05 1979-12-19 Kali Chemie Pharma Gmbh Medical preparation with improved absorbability and production

Also Published As

Publication number Publication date
JPS5754116A (en) 1982-03-31

Similar Documents

Publication Publication Date Title
US4254099A (en) Pharmaceutical tablet composition
JP3667778B2 (en) Spheroid preparation
JP4969104B2 (en) Porous cellulose aggregate and molded body composition thereof
FI72647B (en) FOERFARANDE FOER FRAMSTAELLNING AV ETT PULVER, SOM KAN REKONSTITUERAS GENOM TILLSATS AV VATTEN FOER ERHAOLLANDE AV EN PHARMACEUTICAL SUSPENSION AV BACAMPICILLINSYRAADDITIONSSALTMIKROKAPSLAR I ETT VATTENSUSPENS
DE4240430B4 (en) Stabilized pharmaceutical agent containing an HMG-CoA reductase inhibitor drug
JP5650532B2 (en) New excipient for mannitol tableting
JPH0122245B2 (en)
WO1988006457A1 (en) Medicinal composition containing albumin as carrier and process for its preparation
KR19990013918A (en) Simethicone / Anhydrous Calcium Phosphate Composition
TW200831115A (en) Manufacture process
KR100240362B1 (en) Colestipol hydrochloride high-content tablets
JP2002501015A (en) Solid pharmaceuticals containing miltefosine for oral administration in the treatment of leishmaniasis
JPS61148115A (en) Sustained release pharmaceutical of slightly soluble drug and production thereof
SE433170B (en) PROCEDURE FOR PREPARING A PHARMACOLOGICAL ACCEPTABLE COMPOSITION COMPREHENSIVE HYGROSCOPIC POLY - / (METHYL- (3-TRIMETYLAMMONIOPROPYL) IMINIO) TRIMETYLENE-DICHLORIDE /
CN1857676A (en) Zedoary oil microcapsule preparation and its preparing process
AU626610B2 (en) Sustained release compositions using as matrix hemicellulose extracted from wheat bran
EP1618873B1 (en) Granule for the controlled release of tamsulosin, containing alginate
JPS60255737A (en) Dihydropyridine composition
US8062664B2 (en) Process for preparing formulations of lipid-regulating drugs
JPH029007B2 (en)
EP0425298A2 (en) Sustained-release preparation of basic medical agent hydrochloride
JPH0335287B2 (en)
CN101385717B (en) Solid dispersion containing sofalcone as active ingredient and preparation method thereof
JPS60255736A (en) Nifedipine preparation
JPH0335286B2 (en)